Dendritic cell derived-exosomes:: biology and clinical implementations

被引:118
作者
Chaput, Nathalie [1 ]
Flament, Caroline
Viaud, Sophie
Taieb, Julien
Roux, Stephan
Spatz, Alain
Andre, Fabrice
LePecq, Jean-Bernard
Boussac, Muriel
Garin, Jerome
Amigorena, Sebastian
Thery, Clotilde
Zitvogel, Laurence
机构
[1] Inst Gustave Roussy, CIC Biotherapie, Dept Biol & Pathol, F-94805 Villejuif, France
[2] Univ Paris 11, Fac Med Paris Sud, INSERM, ERM0208, Villejuif, France
[3] Anosys Inc, Menlo Pk, CA USA
[4] CEA, Lab Chim Prot, Grenoble, France
[5] Inst Curie, U365, INSERM, U520, Paris, France
关键词
cytotoxic T lymphocytes; NK cells; tumor immunotherapy; clinical trial;
D O I
10.1189/jlb.0206094
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Exosomes are nanometer-sized membrane vesicles invaginating from multivesicular bodies and secreted from different cell types. They represent an "in vitro" discovery, but vesicles with the hallmarks of exosomes are present in vivo in germinal centers and biological fluids. Their protein and lipid composition is unique and could account for their expanding functions such as eradication of obsolete proteins, antigen presentation, or "Trojan horses" for viruses or prions. The potential of dendritic cell-derived exosomes (Dex) as cell-free cancer vaccines is addressed in this review. Lessons learned from the pioneering clinical trials allowed reassessment of the priming capacities of Dex in preclinical models, optimizing clinical protocols, and delineating novel, biological features of Dex in cancer patients.
引用
收藏
页码:471 / 478
页数:8
相关论文
共 61 条
  • [1] Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T gondii infection
    Aline, F
    Bout, D
    Amigorena, S
    Roingeard, P
    Dimier-Poisson, I
    [J]. INFECTION AND IMMUNITY, 2004, 72 (07) : 4127 - 4137
  • [2] Exosomes as potent cell-free peptide-based vaccine.: I.: Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells
    André, F
    Chaput, N
    Schartz, NEC
    Flament, C
    Aubert, N
    Bernard, J
    Lemonnier, F
    Raposo, G
    Escudier, B
    Hsu, DH
    Tursz, T
    Amigorena, S
    Angevin, E
    Zitvogel, L
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (04) : 2126 - 2136
  • [3] Malignant effusions and immunogenic tumour-derived exosomes
    Andre, F
    Schartz, NEC
    Movassagh, M
    Flament, C
    Pautier, P
    Morice, P
    Pomel, C
    Lhomme, C
    Escudier, B
    Le Chevalier, T
    Tursz, T
    Amigorena, S
    Raposo, G
    Angevin, E
    Zitvogel, L
    [J]. LANCET, 2002, 360 (9329) : 295 - 305
  • [4] Tumor-derived exosomes:: a new source of tumor rejection antigens
    André, F
    Scharz, NEC
    Chaput, N
    Flament, C
    Raposo, G
    Amigorena, S
    Angevin, E
    Zitvogel, L
    [J]. VACCINE, 2002, 20 : A28 - A31
  • [5] Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles
    Andreola, G
    Rivoltini, L
    Castelli, C
    Huber, V
    Perego, P
    Deho, P
    Squarcina, P
    Accornero, P
    Lozupone, F
    Lugini, L
    Stringaro, A
    Molinari, A
    Arancia, G
    Gentile, M
    Parmiani, G
    Fais, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) : 1303 - 1316
  • [6] Alternative mechanism by which IFN-γ enhances tumor recognition:: Active release of heat shock protein 72
    Bausero, MA
    Gastpar, R
    Multhoff, G
    Asea, A
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (05) : 2900 - 2912
  • [7] TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζ complex
    Blanchard, N
    Lankar, D
    Faure, F
    Regnault, A
    Dumont, C
    Raposo, G
    Hivroz, C
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (07) : 3235 - 3241
  • [8] Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Borg, C
    Terme, M
    Taïeb, J
    Ménard, C
    Flament, C
    Robert, C
    Maruyama, K
    Wakasugi, H
    Angevin, E
    Thielemans, K
    Le Cesne, A
    Chung-Scott, V
    Lazar, V
    Tchou, I
    Crépineau, F
    Lemoine, F
    Bernard, J
    Fletcher, JA
    Turhan, A
    Blay, JY
    Spatz, A
    Emile, JF
    Heinrich, MC
    Mécheri, S
    Tursz, T
    Zitvogel, L
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) : 379 - 388
  • [9] Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
    Casares, N
    Pequignot, MO
    Tesniere, A
    Ghiringhelli, F
    Roux, S
    Chaput, N
    Schmitt, E
    Hamai, A
    Hervas-Stubbs, S
    Obeid, M
    Coutant, F
    Métivier, D
    Pichard, E
    Aucouturier, P
    Pierron, G
    Garrido, C
    Zitvogel, L
    Kroemer, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) : 1691 - 1701
  • [10] Exosomes as potent cell-free peptide-based vaccine.: II.: Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection
    Chaput, N
    Schartz, NEC
    André, F
    Taïeb, J
    Novault, S
    Bonnaventure, P
    Aubert, N
    Bernard, J
    Lemonnier, F
    Merad, M
    Adema, G
    Adams, M
    Ferrantini, M
    Carpentier, AF
    Escudier, B
    Tursz, T
    Angevin, E
    Zitvogel, L
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (04) : 2137 - 2146